Claims for Patent: 10,722,502
✉ Email this page to a colleague
Summary for Patent: 10,722,502
| Title: | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| Abstract: | Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1). |
| Inventor(s): | Zhe Li, Stephan D. PARENT, Travis HOUSTON |
| Assignee: | Global Blood Therapeutics Inc |
| Application Number: | US16/163,942 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,722,502 |
| Patent Claims: |
1. A composition comprising a crystalline ansolvate of Compound 1: characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37 ° , 14.37 ° , 19.95° and 23.92 °2 θ (each ±0.2 °2θ), wherein the composition is substantially free of other ansolvate polymorphs of Compound 1. 2. The composition of claim 1, wherein the crystalline ansolvate of Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5. 3. The composition of claim 1, wherein the crystalline ansolvate of Compound 1 is characterized by an endothermic peak at 97 ± 2 ° C. as measured by differential scanning calorimetry. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch